PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

TRADEN'

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if known				
Application Number	10/589,052	_		
Filing Date	August 10, 2006			
First Named Inventor	Kambiz Shekdar			
Art Unit	1639			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	CHROMO/003	_		

	U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant		
initials*	No.1	Number – Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Documents	Passages or Relevant Figures Appear		
	-		,				

FOREIGN PATENT DOCUMENTS							
Cite No.1	Foreign Patent Document Country Code ¹ – Number ² - Kind Code ³	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶		
		Cite No.¹ Foreign Patent Document Country Code¹ – Number² - Kind	Cite	Cite	Cite No.¹ Country Code¹ – Number² - Kind Cite No.¹ Country Code¹ – Number² - Kind Country Code¹ – Number² - Kind		

NON PATENT LITERATURE DOCUMENTS				
Examiner Cite initials* No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published		
		CONLON et al., "Pyrene excimer signaling molecular beacons for probing nucleic acids," Journal of the American Chemical Society 130(1):336-342 (2008).		
		HATZAKIS et al., "Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy," AIDS 18(17):2261-2267 (2004).		
		HERDEWIJN, P., Ed., "Oligonucleotide Synthesis: Methods and Applications," Methods in Molecular Biology 288, Humana Press Inc. (2005) (Table of Contents).		
		KRAWCZYNSKI et al., "Experimental infectivity studies of genetically engineered monoclonal hepatitis B virus (HBV) polymerase gene mutants in chimpanzees," Hepatology 38(4):S1 251A (2003).		
		MORANDI et al., "Monitoring HCV RNA viral load by locked nucleic acid molecular beacons real time PCR," <i>Journal of Virological Methods</i> 140(1-2) :148-154 (2007).		

Examiner Signature	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			0	Complete if known	
				Application Number	10/589,052
INFO	DRMATION	DISC	CLOSURE	Filing Date	August 10, 2006
STATEMENT BY APPLICANT				First Named Inventor	Kambiz Shekdar
			. 2.07	Art Unit	1639
(use as many sheets as necessary)				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	CHROMO/003

NON PATENT LITERATURE DOCUMENTS	
 MUKEWAR et al., "Segmentation of bionano images for understanding cell dynamics,"	
 IEEE Engineering in Medicine and Biology Society 3:1759-1762 (2004).	
 VICENS et al., "Investigation of molecular beacon aptamer-based bioassay for platelet-	
 derived growth factor detection," Chembiochem 6(5):900-907 (2005).	
ZUO et al., "A novel sandwich assay with molecular beacon as report probe for nucleic	
acids detection on one-dimensional microfluidic beads array," Analytica Chimica Acta 587(1):9-13 (2007).	

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.